Evidence map›Paper›PMID 26366742›Full record

ArticlePloS one2015

Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus.

Katie Falloon, Praveen R Juvvadi, Amber D Richards, José M Vargas-Muñiz, Hilary Renshaw, William J Steinbach

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Whole-chromosome duplications drive antimicrobial resistance inbioRxiv : the preprint server for biology · 2025
    Article
  2. Article
  3. Potential Antifungal Targets forInternational journal of molecular sciences · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Antimicrobial agents and chemotherapy · 2018
    Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Katie FalloonDuke University School of Medicine, Durham, NC, United States of America.
Praveen R JuvvadiDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, NC, United States of America.
Amber D RichardsDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, NC, United States of America.
José M Vargas-MuñizDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, United States of America.
Hilary RenshawDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, United States of America.
William J SteinbachDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, NC, United States of America; Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, United States of America.
Duke Medical Center · USDuke University · US

Funding

Trehalose Pathway for Antifungal Targets and InhibitorsP01AI104533 · NIAID · DUKE UNIVERSITY · PI PERFECT, JOHN R. · 2015 to 2019
$9.0M
Structural Biological Development of Fungal-Specific Calcineurin InhibitorsR01AI112595 · NIAID · DUKE UNIVERSITY · PI HEITMAN, JOSEPH, SCHUMACHER, MARIA · 2014 to 2017
$2.5M
NIAID NIH HHS 1R01AI112595NIAID NIH HHS P01 AI104533NIAID NIH HHS R01 AI112595
6 · The paper itself

Abstract

Invasive aspergillosis, largely caused by Aspergillus fumigatus, is responsible for a growing number of deaths among immunosuppressed patients. Immunosuppressants such as FK506 (tacrolimus) that target calcineurin have shown promise for antifungal drug development. FK506-binding proteins (FKBPs) form a complex with calcineurin in the presence of FK506 (FKBP12-FK506) and inhibit calcineurin activity. Research on FKBPs in fungi is limited, and none of the FKBPs have been previously characterized in A. fumigatus. We identified four orthologous genes of FKBP12, the human FK506 binding partner, in A. fumigatus and designated them fkbp12-1, fkbp12-2, fkbp12-3, and fkbp12-4. Deletional analysis of the four genes revealed that the Δfkbp12-1 strain was resistant to FK506, indicating FKBP12-1 as the key mediator of FK506-binding to calcineurin. The endogenously expressed FKBP12-1-EGFP fusion protein localized to the cytoplasm and nuclei under normal growth conditions but also to the hyphal septa following FK506 treatment, revealing its interaction with calcineurin. The FKBP12-1-EGFP fusion protein didn't localize at the septa in the presence of FK506 in the cnaA deletion background, confirming its interaction with calcineurin. Testing of all deletion strains in the Galleria mellonella model of aspergillosis suggested that these proteins don't play an important role in virulence. While the Δfkbp12-2 and Δfkbp12-3 strains didn't show any discernable phenotype, the Δfkbp12-4 strain displayed slight growth defect under normal growth conditions and inhibition of the caspofungin-mediated "paradoxical growth effect" at higher concentrations of the antifungal caspofungin. Together, these results indicate that while only FKBP12-1 is the bona fide binding partner of FK506, leading to the inhibition of calcineurin in A. fumigatus, FKBP12-4 may play a role in basal growth and the caspofungin-mediated paradoxical growth response. Exploitation of differences between A. fumigatus FKBP12-1 and human FKBP12 will be critical for the generation of fungal-specific FK506 analogs to inhibit fungal calcineurin and treat invasive fungal disease.

Indexed as

AnimalsAntifungal AgentsAspergillus fumigatusCalcineurinCaspofunginCyclosporineEchinocandinsGene DeletionHumansHyphaeLipopeptidesMicrobial Sensitivity TestsMothsPhylogenyTacrolimusTacrolimus Binding Protein 1AAntifungal AgentsCalcineurinCaspofunginCyclosporineEchinocandinsLipopeptidesTacrolimusTacrolimus Binding Protein 1A

Identifiers

PMID26366742
PMCPMC4569257
OpenAlexW2201077705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.